NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01112826,Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer,https://clinicaltrials.gov/study/NCT01112826,SYSUCC-001,COMPLETED,The primary objective of this study is to compare disease-free survival (DFS) of patients with triple negative breast cancer randomised to treatment with standard adjuvant chemotherapy alone or to standard adjuvant chemotherapy followed by 1 year of Capecitabine (Xeloda) metronomic therapy.,NO,Breast Cancer,DRUG: Capecitabine,"disease-free survival, The final analysis are expected to occur 36 months after the end of recruitment., 36 months",,,Sun Yat-sen University,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,443,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SYSUCC-001,2010-04-23,2019-12-31,2019-12-31,2010-04-28,,2020-05-27,"Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, 510060, China",
